154 related articles for article (PubMed ID: 28485375)
1. Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Rodríguez-Veiga R; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenomics J; 2018 Apr; 18(2):301-307. PubMed ID: 28485375
[TBL] [Abstract][Full Text] [Related]
2. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Rojas L; Martínez-Cuadrón D; Hervás D; Boluda B; García-Robles A; Rodríguez-Veiga R; Martín-Cerezuela M; Cervera J; Sendra L; Sanz J; Miguel A; Lorenzo I; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 May; 58(5):1197-1206. PubMed ID: 27701910
[TBL] [Abstract][Full Text] [Related]
3. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
4. NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2.
Muise AM; Xu W; Guo CH; Walters TD; Wolters VM; Fattouh R; Lam GY; Hu P; Murchie R; Sherlock M; Gana JC; ; Russell RK; Glogauer M; Duerr RH; Cho JH; Lees CW; Satsangi J; Wilson DC; Paterson AD; Griffiths AM; Silverberg MS; Brumell JH
Gut; 2012 Jul; 61(7):1028-35. PubMed ID: 21900546
[TBL] [Abstract][Full Text] [Related]
5. Role of Ras-related C3 botulinum toxin substrate 2 (Rac2), NADPH oxidase and reactive oxygen species in diallyl disulphide-induced apoptosis of human leukaemia HL-60 cells.
Yi L; Ji XX; Tan H; Lin M; Tang Y; Wen L; Ma YH; Su Q
Clin Exp Pharmacol Physiol; 2010 Dec; 37(12):1147-53. PubMed ID: 20804509
[TBL] [Abstract][Full Text] [Related]
6. Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Poveda JL; Sanz MÁ; Aliño SF
Pharmacogenet Genomics; 2017 Jul; 27(7):270-274. PubMed ID: 28570300
[TBL] [Abstract][Full Text] [Related]
7. Association of
Zhang TP; Li R; Huang Q; Pan HF; Ye DQ; Li XM
J Immunol Res; 2020; 2020():8528976. PubMed ID: 33145364
[TBL] [Abstract][Full Text] [Related]
8. Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz MÁ; Aliño SF; Montesinos P
Pharmacogenet Genomics; 2021 Aug; 31(6):133-139. PubMed ID: 33675324
[TBL] [Abstract][Full Text] [Related]
9. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms.
Cascales A; Pastor-Quirante F; Sánchez-Vega B; Luengo-Gil G; Corral J; Ortuño-Pacheco G; Vicente V; de la Peña FA
Oncologist; 2013; 18(4):446-53. PubMed ID: 23576480
[TBL] [Abstract][Full Text] [Related]
10. Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; Martínez-Cuadrón D; Herrero MJ; Rodríguez-Veiga R; Solana-Altabella A; Boluda B; Ballesta-López O; Cano I; Acuña-Cruz E; Cervera J; Poveda JL; Sanz M; Aliño SF; Montesinos P
Leuk Lymphoma; 2021 Mar; 62(3):659-668. PubMed ID: 33135528
[TBL] [Abstract][Full Text] [Related]
11. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma.
Reichwagen A; Ziepert M; Kreuz M; Gödtel-Armbrust U; Rixecker T; Poeschel V; Reza Toliat M; Nürnberg P; Tzvetkov M; Deng S; Trümper L; Hasenfuss G; Pfreundschuh M; Wojnowski L
Pharmacogenomics; 2015; 16(4):361-72. PubMed ID: 25823784
[TBL] [Abstract][Full Text] [Related]
12. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population.
Rabelo F; Stefano JT; Cavaleiro AM; Lima RVC; de Campos Mazo DF; Carrilho FJ; Correa-Giannella ML; Oliveira CP
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):330-335. PubMed ID: 30087027
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21.
Rossi D; Rasi S; Franceschetti S; Capello D; Castelli A; De Paoli L; Ramponi A; Chiappella A; Pogliani EM; Vitolo U; Kwee I; Bertoni F; Conconi A; Gaidano G
Leukemia; 2009 Jun; 23(6):1118-26. PubMed ID: 19448608
[TBL] [Abstract][Full Text] [Related]
14. [Relationships between the gene polymorphisms of drug metabolizing enzymes and the outcome of the first induction chemotherapy in patients with de novo acute myeloid leukemia].
Wang N; Han JL; Mi YC; Xiao ZJ; Feng SZ; Zhou YL; Wang JX; Han MZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):327-31. PubMed ID: 21518482
[TBL] [Abstract][Full Text] [Related]
15. A functional polymorphism in the NAD(P)H oxidase subunit CYBA is related to gene expression, enzyme activity, and outcome in non-Hodgkin lymphoma.
Hoffmann M; Schirmer MA; Tzvetkov MV; Kreuz M; Ziepert M; Wojnowski L; Kube D; Pfreundschuh M; Trümper L; Loeffler M; Brockmöller J;
Cancer Res; 2010 Mar; 70(6):2328-38. PubMed ID: 20215507
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Genomic Correlates of Neutrophil Reactive Oxygen Species Production in Pediatric Patients With Crohn's Disease.
Denson LA; Jurickova I; Karns R; Shaw KA; Cutler DJ; Okou DT; Dodd A; Quinn K; Mondal K; Aronow BJ; Haberman Y; Linn A; Price A; Bezold R; Lake K; Jackson K; Walters TD; Griffiths A; Baldassano RN; Noe JD; Hyams JS; Crandall WV; Kirschner BS; Heyman MB; Snapper S; Guthery SL; Dubinsky MC; Leleiko NS; Otley AR; Xavier RJ; Stevens C; Daly MJ; Zwick ME; Kugathasan S
Gastroenterology; 2018 Jun; 154(8):2097-2110. PubMed ID: 29454792
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms at microRNA binding sites of Ara-C and anthracyclines-metabolic pathway genes are associated with outcome of acute myeloid leukemia patients.
Cao HX; Miao CF; Yan L; Tang P; Zhang LR; Sun L
J Transl Med; 2017 Nov; 15(1):235. PubMed ID: 29141648
[TBL] [Abstract][Full Text] [Related]
18. CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Seiter K; Ahmed N; Shaikh A; Baskind P; Liu D
Leuk Res; 2016 Jul; 46():74-8. PubMed ID: 27151544
[TBL] [Abstract][Full Text] [Related]
19. Association of genetic polymorphisms NCF4 rs1883112, CBR3 rs1056892, and ABCC1 rs3743527 with the cardiotoxic effects of doxorubicin in children with acute lymphoblastic leukemia.
Gándara-Mireles JA; Lares-Asseff I; Reyes Espinoza EA; Blanco JG; González Font AE; Córdova Hurtado LP; Castañeda VL; Fierro IV; Romero LP; Reyes HA
Pharmacogenet Genomics; 2021 Jul; 31(5):108-115. PubMed ID: 34096893
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
